足够的造血干细胞植入与较低的干细胞剂量。
Adequate Engraftment With Lower Hematopoietic Stem Cell Dose.
机构信息
Division of Hematology and Bone Marrow Transplantation, Max Super-specialty Hospital, Saket, New Delhi, India.
Department of Lab Medicine, Max Super-specialty Hospital, Saket, New Delhi, India.
出版信息
Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):260-263. doi: 10.1016/j.clml.2019.12.018. Epub 2020 Jan 8.
BACKGROUND
Adequate hematopoietic stem cell dose is required to proceed with autologous stem cell transplantation (ASCT).
PATIENTS AND METHODS
We conducted a retrospective analysis of 108 patients with multiple myeloma and lymphoma who underwent ASCT with noncryopreserved stem cells at our center. Data were compared for patients who received stem cell dose < 2 × 10/kg with those who received a higher dose.
RESULTS
The median CD34 dose collected in the lesser dose group was 1.76 × 10/kg (1.22 to 1.97 × 10/kg). Mean CD34 dose of the whole group was 4.96 ± 4.2 × 10/kg. Neutrophil engraftment was similar in both groups (12 vs. 11 days) (P = .065). Similarly, platelet engraftment occurred in 12 versus 11 days in both groups (P = .017). Length of hospital stay was similar in both groups. There was no significant difference in the incidence of proven bacterial infections between the 2 groups. There was no transplant-related mortality in lower dose group.
CONCLUSION
ASCT can be safely performed with lower hematopoietic stem cell dose in noncryopreserved setting.
背景
进行自体干细胞移植（ASCT）需要足够的造血干细胞剂量。
患者和方法
我们对在我们中心接受非冷冻保存干细胞的 108 例多发性骨髓瘤和淋巴瘤患者进行了回顾性分析。比较了接受干细胞剂量<2×10/kg 的患者与接受更高剂量的患者的数据。
结果
低剂量组采集的中位数 CD34 剂量为 1.76×10/kg（1.22 至 1.97×10/kg）。全组平均 CD34 剂量为 4.96±4.2×10/kg。两组中性粒细胞植入相似（12 天对 11 天）（P=0.065）。同样，两组血小板植入分别为 12 天和 11 天（P=0.017）。两组的住院时间相似。两组证实细菌感染的发生率无显著差异。低剂量组无移植相关死亡。
结论
在非冷冻保存环境下，ASCT 可以用较低的造血干细胞剂量安全进行。
Zotero 插件